RPRX
Royalty Pharma Plc
NASDAQ: RPRX · HEALTHCARE · BIOTECHNOLOGY
$49.49
-0.10% today
Updated 2026-04-29
Market cap
$29.37B
P/E ratio
27.83
P/S ratio
12.35x
EPS (TTM)
$1.78
Dividend yield
1.77%
52W range
$31 – $50
Volume
3.2M
WallStSmart proprietary scores
57
out of 100
Grade: C+
Hold
Investment rating
4.7
Growth
C3.5
Quality
D8.0
Profitability
A4.0
Valuation
C2/9
Piotroski F-Score
Weak
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$52.44
+5.96%
12-Month target
$45.61
-7.84%
Intrinsic (DCF)
$39.62
Margin of safety
-11.69%
2 Strong Buy6 Buy2 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 32.40% — above average
+ Free cash flow $827.15M — positive
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.15 — distress zone
- 11.69% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $2.24B | $2.35B | $2.26B | $2.38B | $2.38B | $2.5B |
| Net income | $42.83M | $1.13B | $858.98M | $770.95M | $214.21M | — |
| EPS | — | — | — | — | $1.78 | $5.17 |
| Free cash flow | $102.83M | $872.28M | $2.77B | $2.49B | $827.15M | — |
| Profit margin | 1.91% | 48.20% | 37.95% | 32.42% | 32.40% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | COYNE, TERRANCE P. | Sale | 32,916 | $48.33 |
| 2026-04-01 | COYNE, TERRANCE P. | Sale | 1,875 | $48.33 |
| 2026-03-31 | BASSLER, BONNIE L | Buy | 815 | $45.98 |
Peer comparison
Smart narrative
Royalty Pharma Plc trades at $49.49. representing a P/E of 27.83x trailing earnings. Our Smart Value Score of 57/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.15, it sits in the distress. TTM revenue stands at $2.38B. with profit margins at 32.40%. Our DCF model estimates intrinsic value at $39.62.
Frequently asked questions
What is Royalty Pharma Plc's stock price?
Royalty Pharma Plc (RPRX) trades at $49.49.
Is Royalty Pharma Plc overvalued?
Smart Value Score 57/100 (Grade C+, Hold). DCF value $39.62.
What is the price target of Royalty Pharma Plc (RPRX)?
The analyst target price is $52.44, representing +6.0% upside from the current price of $49.49.
What is the intrinsic value of Royalty Pharma Plc (RPRX)?
Based on our DCF model, intrinsic value is $39.62, a -11.7% margin of safety versus $49.49.
What is Royalty Pharma Plc's revenue?
TTM revenue is $2.38B.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
1.15 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.35x
ROE13.20%
Beta0.39
50D MA$47.07
200D MA$40.34
Shares out0.44B
Float0.42B
Short ratio—
Avg volume3.2M
Performance
1 week+0.22%
1 month+2.06%
3 months+18.74%
YTD+28.08%
1 year—
3 years—
5 years—